PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Product: PSB202 is a novel biological entity consisting of two engineered monoclonal
antibodies, an Fc-enhanced humanized type II anti-CD20 IgG1 (PSB102) and a humanized
anti-CD37 IgG1 (PSB107), that target B-cells. PSB202 is manufactured to work as a single
product with the two components of PSB202 enabling a distinct dual target-specific antibody
directed cell killing of B-cells.
Study: Multi-center-, International Phase 1a/1b (Escalation/Expansion) study in patients with
indolent-, relapsed-, B-cell malignancies. The Phase 1a (Dose Escalation) part of study
follows a 3+3 design.